PHASE Scientific Earns Prestigious Recognition at 2025 ASCCP Scientific Meeting for Innovation in Urine-Based HPV Screening
SAN DIEGO, April 29, 2025 /PRNewswire/ -- PHASE Scientific (PHASE) proudly announced a major milestone this week with its inaugural participation and award-winning presentation at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting — one of the foremost global events dedicated to advancing women's health.
Held in San Diego from April 24–26, the ASCCP Scientific Meeting serves as a critical platform for shaping the future of cervical cancer prevention and diagnosis, bringing together leading clinicians, researchers, and healthcare innovators from around the world. As the recognized authority on cervical cancer screening guidelines and education for U.S. obstetricians and gynecologists, ASCCP represents an unparalleled stage for groundbreaking research.
In collaboration with PHASE, Peking University Shenzhen Hospital (PUSH) presented groundbreaking research on urine-based HPV testing at the Scientific Meeting. The study, which utilized PHASE's proprietary technologies, was awarded the Thomas V. Sedlacek, MD, Prize for Best Clinical Research Abstract — a top recognition for excellence in clinical research. This marks a significant achievement and highlights the growing momentum toward non-invasive cervical cancer screening approaches.
The award-winning study showcased the performance of PHASE's novel technologies: PHASiFY™, an advanced urine DNA concentration method, and the PhaseLab™ HPV Urine Test, a next-generation urine-based HPV DNA testing platform. In the study, women undergoing follow-up colposcopy or treatment for high-grade cervical lesions (CIN2/3) provided both urine samples and physician-collected samples for HPV testing. Results demonstrated a >97% concordance between urine-based PhaseLab™ testing and standard physician-collected testing (Cobas 4800) for detecting HPV types 16 and 18, along with comparable performance in detecting cervical precancerous lesions.
"We are proud that PHASE Scientific's technologies, including our PHASiFY™ system, supported this important research presented by Peking University Shenzhen Hospital at the ASCCP Scientific Meeting," said Dr. Ricky Chiu, Chairman and CEO of PHASE Scientific. "The findings demonstrate that PHASiFY™ significantly enhances the detection of cervical precancers through simple, non-invasive urine samples — a transformative step toward making cervical cancer screening more accessible and patient-centered. We remain deeply committed to driving innovations that advance women's health."
The presentation sparked strong interest and discussion among leading industry experts and healthcare professionals, reinforcing the growing momentum behind non-invasive cervical cancer screening. PHASE Scientific is honored to contribute to this important movement and looks forward to continuing to develop solutions that reduce barriers to screening, and ultimately help eliminate cervical cancer as a public health threat.
Disclaimer: PhaseLab™ HPV Urine Test is available in the US for the detection of HPV DNA only and has not been approved for use as a cervical cancer screening test.
About PHASE Scientific
PHASE Scientific is a fast-growing biotech company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management.
SOURCE PHASE Scientific
Share this article